Full Breakdown
Novo Nordisk Q2 Results Show Profit Rise but Wegovy Pill Miss Dampens Investor Sentiment
8/5/2026, 4:21:04 AM
Q2 Earnings and Revised Outlook
On August 4, Novo Nordisk reported second-quarter sales of 78.49 billion Danish crowns, a 3 % increase in constant currency, and an adjusted operating profit up 11 % year-on-year. The company lifted its 2026 full-year outlook, now expecting adjusted sales to fall between 0 % and -6 % (versus a prior range of -12 % to -4 %) and adjusted operating profit to be flat to -6 % (previously -12 % to -4 %). Despite the higher guidance, U.S.-listed shares slipped about 6 % as investors focused on a modest miss for the new oral Wegovy pill.
Pipeline Setbacks
Novo’s next-generation obesity candidate CagriSema matched Eli Lilly’s tirzepatide on weight loss in a 68-week head-to-head trial but failed to outperform on blood-sugar control, delivering a non-inferiority result rather than superiority. In a separate late-stage study, the experimental cardiovascular drug ziltivekimab did not reduce major heart-event risk, adding to concerns about the firm’s pipeline beyond its blockbuster semaglutide platform.
Market and Analyst Reaction
Analysts highlighted the pill’s sales of 3.22 billion crowns, slightly below the 3.27 billion-crown consensus, and warned that deep U.S. discounts could pressure pricing. Sydbank’s Søren Lontoft Hansen stressed the need for a successor to semaglutide before patent expiries.
Company Statements
CEO Mike Doustdar, who took the helm a year ago, said the oral Wegovy pill has already surpassed 5 million prescriptions since its January launch. Novo also cited a “most-favored-nation” pricing agreement with President Donald Trump as a factor in lower realized U.S. prices and warned that reduced Medicaid coverage for obesity medicines would weigh on future sales.
Verbatim Quotes
- “The only surprise I see is that oral Wegovy was just in line with expectations,” — Markus Manns, portfolio manager at investor Union Investment
- “They are confirming this non-inferiority ... which really just means that it's no better than Lilly's products,” — Jyske Bank
- “We think the lack of upside for Wegovy pill vs. models has stock down,” — Jared Holz, Mizuho Securities healthcare sector specialist
*Data note:* Reuters cites adjusted operating profit of 33.4 billion crowns, while CNBC reports 33.39 billion crowns for the same quarter.
